BridgeBio Oncology Therapeutics, Inc. cotiza a 2.95 USD y tiene una capitalización bursátil de $236M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule dir…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-0.49 | $-1.03 |
| Estimado | $-0.66 | $-0.54 | $-0.66 | $-0.34 |
| Sorpresa | — | — | +25.8% | -202.9% |
| Métrica | BBOT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -32.6% | -40.4% | +7.8% |
| ROA | -29.9% | -32.0% | +2.1% |
| Current Ratio | 12.34 | 2.84 | +9.50 |
| Debt / Equity | — | 0.28 | — |